Alissa Noeska
Family Medicine · Elgin, ILNPI 1710604822
Payments from drug & device makers
Across 146 payments — averaging $20.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$501
- AbbVie$473
- Pfizer$438
- Lilly USA, LLC$269
- Phathom Pharmaceuticals, Inc.$182
- Otsuka America Pharmaceutical, Inc.$179
- plus $942 from 21 others
What the payments were for
- Food & beverage$2,985100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 23 | $501 |
| AbbVie | 22 | $473 |
| Pfizer | 27 | $438 |
| Lilly USA, LLC | 13 | $269 |
| Phathom Pharmaceuticals, Inc. | 9 | $182 |
| Otsuka America Pharmaceutical, Inc. | 7 | $179 |
| Novartis | 7 | $160 |
| Boehringer Ingelheim | 6 | $119 |
| AstraZeneca | 6 | $105 |
| GSK | 3 | $63 |
| Johnson & Johnson | 3 | $57 |
| Sanofi Pasteur Inc. | 2 | $43 |
| Exact Sciences | 2 | $43 |
| Astellas Pharma US Inc | 2 | $35 |
| Hologic Sales And Service, LLC | 2 | $35 |
| Axsome Therapeutics, Inc. | 1 | $30 |
| Angiodynamics, Inc. | 1 | $30 |
| Bayer | 1 | $28 |
| Averitas Pharma Inc. | 1 | $26 |
| Dexcom, Inc. | 1 | $25 |
| Seqirus USA Inc | 1 | $23 |
| Impel Pharmaceuticals Inc. | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Biogen | 1 | $20 |
| Philips North America LLC | 1 | $20 |
| Exeltis, USA Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,985 in reported general payments places this provider in the 85th percentile of 4,116 family medicine providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 31 | $31,264 |
| JardianceEmpagliflozin | 12 | $8,178 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 44 | $1,013 |
| Potassium Chloride | 14 | $740 |
| Omeprazole | 41 | $687 |
| Levothyroxine Sodium | 54 | $594 |
| Atorvastatin Calcium | 86 | $554 |
| Ibandronate Sodium | 15 | $506 |
| Lisinopril | 52 | $426 |
| Losartan Potassium | 51 | $423 |
| Gabapentin | 22 | $393 |
| Fenofibrate | 12 | $383 |
| Sertraline Hcl | 44 | $377 |
| Fluticasone Propionate | 18 | $338 |
| Metformin Hcl | 47 | $290 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $501 | $31,26431 claims |
| Boehringer IngelheimJardiance | $119 | $8,17812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Elgin
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
- Mark ChristensenNew Lenox$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.